Recently, novel SS18::SSX and SSX C-terminus–specific antibodies have shown high sensitivity and specificity for synovial sarcoma, offering the potential for immunohistochemistry to replace molecular genetics in most cases. This evidence concerns the gene SS18 and synovial sarcoma.